Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now
Evaluates Manufacture Of Recently Incentivized APIs
Executive Summary
Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.
You may also be interested in...
COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
India Lockdown: Early Signs of Manufacturing Strains But Resolutions Underway
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
FDA Scales Back Domestic Inspections Due To Coronavirus
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.